Aspen Pharmacare Wins Approval for Generic Semaglutide
The South African drugmaker plans to launch its generic injectable version in Canada, Brazil and South Africa in the coming months.
Updated on Nov. 11, 2026 in Diabetes
Live Poll
Would you switch to a cheaper generic version of a GLP-1 drug if available?
Aspen Pharmacare has received regulatory approval in Brazil and South Africa for its generic injectable semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. The company expects to begin commercializing the product in Canada, Brazil and South Africa in the coming months.
Why it matters
Semaglutide has lost patent protection, prompting drugmakers to race to launch lower-cost versions. Aspen is betting that generic supply can drive growth in emerging markets and selected international markets.
South African GLP-1 medicine sales have grown to nearly 3 billion rand ($182 million), with Eli Lilly's Mounjaro holding more than half of that market. Aspen has not disclosed launch pricing or a firm date for Canadian commercialization.
The players
Aspen Pharmacare
A South African pharmaceutical company that manufactures and distributes generic and branded medicines across Africa and other international markets.
Novo Nordisk
A Danish pharmaceutical company and the originator of semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss.
Eli Lilly
A U.S. pharmaceutical company whose drug Mounjaro holds more than half of the South African GLP-1 market.
Dr. Reddy's Laboratories
An Indian pharmaceutical company supplying the active pharmaceutical ingredient for Aspen's Canadian market launch.
The details
Aspen Pharmacare is sourcing the active pharmaceutical ingredient from third-party suppliers, including India's Dr. Reddy's Laboratories for the Canadian market. The company already distributes Eli Lilly's Mounjaro across sub-Saharan Africa, a position it is now extending into generic semaglutide.
Timeline
November 11, 2026: Aspen announced regulatory approvals in Brazil and South Africa.
Coming months: Planned commercial launch in Canada, Brazil and South Africa.
Market Landscape
The loss of semaglutide's patent protection has triggered a race among drugmakers to launch lower-cost versions of the GLP-1 medicine. Aspen's approvals position it to compete in emerging markets where branded GLP-1 drugs have grown rapidly.
Generic semaglutide could eventually lower the cost of GLP-1 treatment for people with diabetes or obesity in the markets where it launches. Patients should confirm availability and pricing with local pharmacies or prescribers once the product reaches their country.
The takeaway
Lower-cost generic versions of GLP-1 medicines may widen access in markets where branded drugs have been expensive. Patients interested in these treatments should watch for launch announcements in their own countries.
Further reading
Explore more on Diabetes to see how GLP-1 treatments are shaping care worldwide.
Live Poll
Would you switch to a cheaper generic version of a GLP-1 drug if available?
